Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAST trial of omalizumab to inhibit mast cell activation in atherosclerotic plaques
2019-002452-16Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis comparing omalizumab with placebo (2 arms). Primary endpoint: Activated mast cell percentage in plaque. Started Feb 2020; status: active.
02
Drugs
omalizumab
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on 2019-002452-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002452-16.